Dr. Jeff Settleman, Ph.D., Chief Scientific Officer, Oncology Research and Development, Pfizer
Advertisement
Articles by Dr. Jeff Settleman, Ph.D., Chief Scientific Officer, Oncology Research and Development, Pfizer
Advertisement
Latest Updated Articles
- Bispecific antibodies in multiple myeloma: revolutionizing blood cancer immunotherapy
Published: June 21st 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5